Dr Georgios Angelis received his bachelor’s degree in Electrical and Computer Engineering from the National Technical University of Athens, Greece in 2007. He completed his Ph.D. in Biomedical Engineering at the University of Manchester, UK in 2011 working in the field of spatiotemporal (4D) Positron Emission Tomography image reconstruction and parameter estimation for applications in neuroscience. In 2012 he moved to Australia to pursue a postdoctoral position within the internationally recognised Imaging Physics group, based at the University of Sydney’s Brain and Mind Centre, which has pioneered the use of motion tracking and correction for quantitative imaging of conscious and freely moving rodents. He worked on challenging technical problems, such as the accurate modelling of animal motion within the imaging system, the complex photon attenuation field of a freely moving animal and the mathematical modelling of transient changes in neurotransmitter levels induced by cognitive tasks or pharmacological interventions. Before joining the Australian National Imaging Facility in 2020, he worked for 2 years as a senior research scientist at the Northern Sydney Cancer Centre, Royal North Shore Hospital, developing methods for real-time tumour tracking for motion adaptive radiotherapy. His current research interests include PET/SPECT image reconstruction and optimisation algorithms, pharmacokinetic modelling of physiological processes, machine learning and statistical analysis of multi-dimensional imaging data.
The Australian National Total Body PET Facility, launched just over a year ago, has shown that sharing PET infrastructure has proved to be a cost-effective model – bringing benefits to both patient
03 June 2025
Dr Sicong Tu is excited about helping motor neurone disease (MND) patients gain a much better idea of their disease progression: “The focus of our network is on bridging the gap between leading Aust
28 May 2025
A new national-scale molecular-imaging network that aims to improve cancer imaging, dementia diagnosis and treatment, and new radiopharmaceuticals was launched Saturday at the annual meeting for Austr
26 May 2025
Long-term NIF user and collaborator, AdvanCell has secured $112m in Series C funding supported by Sanofi Ventures to advance its targeted alpha therapy for metastatic prostate cancer.
03 February 2025